InterMune Conference Call to Discuss Second Quarter Financial Results Scheduled for Thursday, July 26, 2001.Business Editors & Medical/Health Writers BRISBANE, Calif.--(BUSINESS WIRE)--July 16, 2001 InterMune Inc. (Nasdaq:ITMN) today announced that it will release second quarter financial results before the markets open on Thursday, July 26, 2001. Company management will host a conference call on Thursday, July 26, 2001 at 10:30 a.m. (EST EST electroshock therapy. EST abbr. electroshock therapy ) to discuss the financial results. To participate in the conference call, please dial 888/209-3911 (domestic) or 415/904-2408 (international) and reference call number 19360213. A telephone replay of the conference call will be available through Monday, July 30, 2001. To access the replay, please dial 800/633-8284 (domestic) or 858/812-6440 (international) and reference call number 19360213. The conference call can also be heard live and on a replay basis through an Internet Webcast, which may be accessed by visiting InterMune's Web site at http://www.intermune.com and clicking on the "Investor Relations" icon. InterMune is developing and commercializing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune markets its lead product, Actimmune(R), for the treatment of chronic granulomatous disease Chronic Granulomatous Disease Definition Chronic granulomatous disease (CGD) is an inherited disorder in which white blood cells lose their ability to destroy certain bacteria and fungi. (CGD) and severe, malignant osteopetrosis. InterMune is currently conducting a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the with Actimmune(R) for the treatment of idiopathic pulmonary fibrosis idiopathic pulmonary fibrosis Idiopathic interstitial fibrosis of lung Pulmonology An idiopathic condition characterized by scarring and fibrosis of alveolar septae more common in middle-aged men, possibly related to collagen vascular disease, with positive (IPF). InterMune is also conducting or planning clinical trials of Actimmune(R) for the treatment of multidrug-resistant tuberculosis (MDR TB), atypical mycobacterial infections Mycobacterial Infections, Atypical Definition Atypical mycobacterial infections are infections caused by several types of mycobacteria similar to the germ that causes tuberculosis. , ovarian cancer, cryptococcal meningitis, cystic fibrosis, liver fibrosis and non-Hodgkin's lymphoma. InterMune recently acquired rights to Infergen(R), which is marketed in the United States and Canada for the treatment of chronic hepatitis C infections. InterMune also markets Amphotec(R) worldwide for the treatment of invasive aspergillosis Aspergillosis Definition Aspergillosis refers to several forms of disease caused by a fungus in the genus Aspergillus. Aspergillosis fungal infections can occur in the ear canal, eyes, nose, sinus cavities, and lungs. . |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion